Table 2.
Patient imaging findings before and after tocilizumab treatment.
| Pt | Gender | Age | PET (Meller scale) at baseline | PET (Meller scale) at follow-up | MRA at baseline | MRA at follow-up | CTA at baseline | CTA at follow-up | CDUS IMT at baseline (mm) | CDUS IMT at follow-up (mm) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 65 | — | — | — | — | — | — | 0.7 (TA) | 0.4 (TA) |
| 2 | F | 64 | III | 0 | — | — | — | — | 0.7 | |
| 3 | F | 70 | III | 0 | Right ICA occlusion; CCA, left SA, and VA thickening | ICA partially recovered; other arteries fully resolved | — | — | 1.5 (CCA) | 0.7 (CCA) |
| 4 | F | 74 | III | 0 | — | — | — | — | — | — |
| 5 | F | 78 | — | — | — | — | — | — | 0.6 (TA) | 0.2 (TA) |
| 6 | F | 56 | III | 0 | — | — | Aortic wall thickening | Negative | — | — |
| 7 | F | 77 | III | I | — | — | Aortic wall thickening | Negative | — | — |
| 8 | M | 60 | III | I | — | — | Aortic wall thickening | Negative | — | — |
| 9 | F | 85 | — | — | — | — | — | — | 0.7 (TA) | 0.3 (TA) |
| 10 | M | 77 | III | 0 | ICA enhancement | Negative | — | — | 1.2 (CCA) | 0.7 (CCA) |
| 11 | M | 65 | III | I | — | — | — | — | 1.4 (AxA) | 0.8 (AxA) |
AxA: axillary artery; CCA: common carotid artery; CDUS: color Doppler ultrasonography; CTA: computed tomography angiography; ICA: internal carotid artery; IMT: intima-media thickness; MRA: magnetic resonance angiography; PET: positron emission tomography; SA: subclavian artery; SUV: standardized uptake value; TA: temporal artery; VA: vertebral artery.